Home › Pfizer's RAPAMUNE (sirolimus) Becomes First FDA-Approved Treatment For Lymphangioleiomyomatosis (LAM), A Rare Progressive Lung Disease
 

Keywords :   


Pfizer's RAPAMUNE (sirolimus) Becomes First FDA-Approved Treatment For Lymphangioleiomyomatosis (LAM), A Rare Progressive Lung Disease

2015-06-03 06:19:12| drugdiscoveryonline Home Page

Pfizer Inc. announced recently that the U.S. Food and Drug Administration (FDA) has approved RAPAMUNE (sirolimus) for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive disease that affects the lungs, kidneys and the lymphatic system

Tags: treatment disease rare progressive

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Farm Progress America, May 20, 2024
20.05Farm Progress America, May 20, 2024
20.05Nielsen launches The Media Distributor Gauge
20.05Minerva AI Companion enhances the TV viewing experience
20.05Ryanair profits surge after fares climb by 20%
20.05SES Ethiosat delivering content to 95% of TV homes in Ethiopia
20.05Vidzemes TV expands with PlayBox Neo Channel-in-a-Box playout
20.05ocilion enhances user experience with Simply.TV metadata
More »